Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Rua Life Sciences Plc | RUA | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 11.50 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 11.50 | 11.50 | 11.50 | 11.50 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 21/11/2024 19:34 by thiopia Just FYI markets aren't efficient so of course you will get occasional mispricings. RUA does have a quite complex story and a history of not achieving anything on the big promises so far so a lot of stale bulls and lack of Institutional interest means we get a double whammy of persistent undervaluation and volatile small volume trading. |
Posted at 21/11/2024 14:42 by bones Marmie, RUA paid €80,000 for total ownership of ABISS. This was a fire sale by the French liquidator out of ABISS’s old holding company. In the last RNS, RUA estimated, based on book values, that the surplus in value over the €80k that needs to be recognised as a non-cash one off addition to assets of the RUA group is around £900k (in GBP it said). This could be subject to change once they’ve worked out what the fair values of the assets are. They probably need to put some value on the IP too. I think there’s a good chance the adjustment might be higher.Also, it sounds like ABISS is cash positive so they might be building cash having owned it for three months so far. Buying ABISS was mostly at the behest of the big customer, Coloplast, and the RUA group has now decided to realign its own year end to that of Coloplast. I don’t regard that as a coincidence. Coloplast has a vested interest in the products ABISS owns and produces for it. RUA’s other contract manufacturing business seems to be going well also. That is profitable in its own right. RUA’s R&D expenditure has been heavily curtailed to save costs too. The current weakness is probably associated with the messaging on the heart valve. There is no way the share price had been factoring in the heart valve anyway (the CM businesses are worth more than the market cap on their own) but it’s a combination of sentiment and simply being a microcap stock in an ignored AIM marketplace. I’m hoping the interims and commentary due in mid December will fill in the latest developments and be positive on these fronts. |
Posted at 21/11/2024 12:03 by cfb2 Marmie, I have pondered a similar question. I'll put myself up as a straw man so that some of the people invested here can correct me.RUA's profit was from the £900k from purchasing Abiss. From what I can discover about Abiss this was a one off but I am struggling to find out what their long term contribution to RUA might be as they are hidden within IPSAS SAS. Without Abiss, RUA are losing around £1m a year and everything BB has touched has turned to sh*t. I have looked at legal/financial liabilities pending for Abiss to justify the low liquidator price but can't find any. |
Posted at 01/11/2024 07:55 by z1co Posted by NickE on lse:Good find Jimzi, and often with smaller medical device companies the P/E ratio is usually higher than that of established players. As you say we can't necessarily apply a P/E of around 64 especially as U.S. companies have a higher P/E assigned than UK stocks. Also, the 900k 'fair value' is I assume a temporary boost to the move to profitability although ABISS will accelerate the move to profitability. Regardless, markets look ahead and a value for a high growth medical device company moving to profitability with other increasingly 'oven ready' blue sky products should be a multiple of where we are now. Following on from the Aortech shareholder base, RUA's history has mainly been in the blue sky sector so value investors probably don't have it on their radar. It's almost as if the stock is punished for being both blue sky and a value play. It may be that the 50p plus valuation the stock probably deserves will only come with full or partial acquisition and on that topic some very astute posts from IntraVnus. RUA do tend to drop hints and when they spoke about doubling revenues they didn't allude to the bargain £80k acquisition but the clue was there. Maybe "the Company has changed its financial year end to better guide business planning and international business unit assimilation" is flagging up another acquisition but this time it's RUA itself. I wonder how that would pan out? They would be interested in contract manufacturing and Elast-Eon but would Coloplast have any need for Rua Vascular and Structural Heart? Unless of course they are looking to expand into long-term implants or soft tissue repair. This quarter could get interesting. |
Posted at 30/10/2024 11:05 by z1co More facts;The gross assets of Abiss at 31 December 2023 were €2,265,000. Revenue in the year to 31 December 2023 was €2,159,000 up 36% from €1,592,000 during 2023. Loss before tax was €352,000 after depreciation and amortisation charges of €537,000. In the year to 31 December 2023, Abiss had net positive cash flow of €223,000 and cash balances of €279,000 at the year end. Net Assets/Shareholders Funds at 31 December 2023 were €1,624,000. Non-current liabilities totalled €640,000 at 31 December 2023. Bill Brown, stated: "There are many similarities between Abiss and RUA Contract Manufacture, particularly with a shared customer. Abiss has been pursuing contract manufacture opportunities to further grow its business and the combined strengths of RUA and Abiss should only increase the potential. We very much look forward to working with the Abiss team and integrating into the RUA group." |
Posted at 03/10/2024 22:16 by thiopia Reminder of the prices Directors/Insiders paid in recent yearsDirectors Deals for Rua Life Sci. (RUA) Announced Traded Action Notifier Price 14-Dec-22 14-Dec-22 Buy Lachlan Smith 54.17 30-Dec-20 30-Dec-20 Placing Geoffrey Alan Berg 120.00 30-Dec-20 30-Dec-20 Placing John Louis Ely 120.00 |
Posted at 08/4/2024 08:41 by rivaldo Cavendish retain their 25p price target in their update this morning (with a £7.8m m/cap at 12.5p).Brief extracts: "Strong strategic progress RUA Life Sciences has provided a business update for the year to March 2024, noting revenue shortfalls experienced in H1/24 have been made up by a strong second half. Revenues for the year are therefore expected to be in-line with our forecast £2.2m, while the company notes gross margin will exceed our forecasts, with operating costs remaining tightly controlled. RUA Life Sciences closed FY24 with cash of c£4.0m versus our £3.3m estimate. The company reports significant progress towards its goal of near-term profitability through growing its contract manufacturing business, noting strong progress with a ‘global enterprise’. Finally, RUA has completed a Material Transfer Agreement with a global Heart Valve company covering its composite heart valve material. We believe this update demonstrates excellent progress against the company’s revised strategy." "Strategy – As noted with its successful fundraise in December 2023, RUA’s revised strategy will seek to grow its Contract Manufacturing business, generating long-term contract revenues, explore third-party funding for its vascular graft portfolio and pursue licence opportunities for its composite heart valve material. We believe this business update demonstrates strong progress against this strategy. - Investment thesis – We believe the combination of established revenues with growth potential and the option to deliver significant returns through the disruption of established billion-dollar global cardiovascular markets makes RUA Life Sciences an attractive investment opportunity. RUA now aims to turn profitable in the short term and has adopted a strategy to deliver earlier returns on its Vascular and Structural Heart investments." |
Posted at 05/4/2024 07:59 by parob Very good update imo. Plenty of cash/time to get sone commercial deals over the line. Speculation alone could drive this higher. Business Update RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon), today provides an update on trading for the financial year ending 31 March 2024 and developments since the successful fundraise in December 2023.TradingThe first half of the financial year was impacted by operational issues, resulting in the delayed shipment of products from the Contract Manufacturing business. As anticipated, the revenue shortfall experienced during H1 has been fully compensated by a strong H2 performance. As a result, the Company expects to report, subject to audit, FY24 revenue of £2.2 million, which is in line with market expectations. The Company is pleased to announce that the recovery in revenues has not been at the cost of gross margins, and it is anticipated that reported margins will exceed expectations. The Group has focussed on cost control throughout the year. These rigorous measures are expected to result in operating costs of £3.4 million, approximately £0.2 million below market expectations for the year.Cash PositionStrong cost management, together with the anticipated recovery in trading during the second half, means the Company remains financially resilient, with a strong balance sheet and a cash position of approximately £4.0m. Despite challenging trading conditions, these achievements underscore the Group's resilience and adeptness in financial and operational management.Business DevelopmentSignifica |
Posted at 26/3/2024 09:59 by hedgehog11 Thanks burtond1, I always enjoy a feel good read, but someone at RUA must write for Total Market Solutions.My favourite quote; "The strategy is showing signs of paying off, with RUA’s Contract Manufacture, Structural Heart and Vascular branches closing in on deals that promise significant longer-term cash generation and profitability." And I must of missed a few RNS' "Another Contract Manufacture customer ‘is expected to submit a bid request in the next few months at a value of around £500,000." If only bid requests earned income. "The company hopes to double its Contract Manufacture business by continuing to convert sales discussions into formal bid processes." When? "RUA’s Vascular division is seeking third party funding for an advanced project that has attracted interest from original equipment manufacturers, and early commercial sales. All the conditions are in place for the commencement of the regulatory testing regime:" interest in what from who? Joking aside, I've not paid much attention recently but these assertions need backing up and I'm pretty sure the correct place to do that would be an RNS! This article is a typical RUA RNS with a positive spin on it. There's no doubt what is says is what everyone is now hoping for. The doubt is not in the products. It is whether they are really is as good as the claims and the ability of the company to get a return from it. A balanced article would have highlighted some of the challenges and failures RUA are experiencing. The frustration is, that if the tide does turn for RUA, the returns from this point will be pretty impressive. |
Posted at 08/6/2023 13:22 by edmonda FY2023 Trading Update - welcome regulatory and R&D progress (and divisional reorganisation)Full details in our note published this morning: Summary: RUA Life Sciences trading update included Group revenues and year-end cash position were modestly ahead of our estimates, with other figures mostly in-line. The highlight of the trading update was the agreement with the FDA on the requirements for the GLP animal study and 120-patient clinical trial required to secure US approval of RUA’s vascular graft. It is clear that RUA is on a pathway to the US approval of its vascular graft which should not be a surprise. RUA Contract Manufacture and RUA Biomaterials both have US customers with approved products. The trading update also provided detail on RUA’s Structural Heart polymeric heart valve product, noting the high bar that heart valves need to reach in terms of their mechanical properties, durability and functionality. RUA’s composite heart valve appears to be meeting these milestones and the current design was proposed as one that could be supplied to other companies. In a subsequent announcement, RUA provided the details of a reorganisation of the Group resulting in its key experimental product businesses – RUA Structural Heart Limited and RUA Vascular Limited – into stand-alone subsidiaries 100% owned by the Group. We applaud this move on a transparency basis which fits with the trading update’s reporting on the segmented sales and net profit margins of RUA’s revenue-generating businesses, RUA Biomaterials and RUA Contract Manufacture. We would caution investors not to jump to the conclusion that one or more of RUA’s segmented divisions could be divested despite the illustrative basis of our valuation being as whole-product acquisitions. Instead, as the timelines for the vascular graft and heart valve products are different, the hive down of the two businesses allows the value and risks of each to be appreciated and provides visibility on where any possible future fundraisings are invested. We await RUA’s final FY 2023 results in mid-July to update our financials and valuation. For now, our valuation remains at £121.0m (545p per share). |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
